Hook & thesis
Hims & Hers (HIMS) has been one of 2026's most talked-about turnaround stories: revenue is growing, management raised full-year guidance, and the company is doubling down on higher-growth categories like weight-loss and international telehealth. Yet the stock trades roughly 54% below its 52-week high of $70.43 and remains volatile after an earnings miss and a $350 million convertible debt raise. I think that volatility creates an actionable long opportunity for disciplined traders willing to tolerate headline risk.
The thesis is straightforward: the company is executing a pivot from margin-rich compounded GLP-1 fulfillment toward reselling branded GLP-1/weight-loss products and scaling internationally via the Eucalyptus acquisition. Those moves compress near-term margins but increase revenue optionality and reduce single-market regulatory risk. With market cap near $7.38 billion and EV/Sales about 3.43, the valuation already prices in considerable execution risk. If topline growth and margin stabilization return over the next 6-9 months, the stock has a clear path back toward $45.
What Hims & Hers does and why the market should care
Hims & Hers operates a consumer-facing telehealth platform across mental health, sexual health, dermatology, primary care and weight-loss. The core benefit to the market is scale and direct-to-consumer distribution: the company connects patients to providers, controls the fulfillment and increasingly sources branded therapeutics to sell through its channel. That mix gives HIMS leverage to capture spend across recurring-care categories and to cross-sell higher-ticket items like GLP-1 drugs.
Investors should care because HIMS sits at the intersection of three durable trends: continued adoption of telehealth services, secular demand for weight-loss therapeutics, and digital-first healthcare distribution. If HIMS can maintain the customer economics and scale international revenue, the business can grow materially while amortizing its technology and marketing investments.
Supporting numbers and recent trends
- Q1 performance: reported revenue of $608.1 million, up 4% year-over-year, and management raised full-year guidance to $2.8-3.0 billion (growth implied from latest run-rate).
- Profitability: Q1 swung to a $92.1 million net loss from a $49.5 million profit a year earlier; adjusted EBITDA guidance was lowered to $275-350 million as gross margins compressed from 73% to 65% due to a shift from refilled compounded GLP-1s to lower-margin branded weight-loss products.
- Capital structure and liquidity: the company announced a $350 million zero-coupon convertible debt to fund expansion (part of a broader $1.15 billion Eucalyptus acquisition). This raises dilution or repayment risk if growth does not accelerate.
- Market snapshot: current price $32.45, market cap approx. $7.38 billion, enterprise value $8.13 billion, EV/Sales 3.43, price-to-sales ~3.11. Free cash flow on the latest basis was ~$66.9 million.
- Technicals: strong short-term momentum with the 10-day SMA at $28.74 and the 50-day SMA at $26.32. RSI near 64.6 and bullish MACD histogram suggest constructive technicals for a momentum-driven recovery.
- Sentiment and positioning: short interest remains elevated — recent settlement counts show ~62.6 million shares short — which can amplify both downside and upside moves in a liquidity event.
Valuation framing
At roughly $7.38 billion market cap and EV of $8.13 billion, HIMS trades at EV/Sales of ~3.43 against current-year revenue guidance of $2.8-3.0 billion. That multiple implies the market expects either weak future growth or persistent margin pressure. Historically, Hims & Hers enjoyed premium multiples when its gross margins were in the low 70s and growth was accelerating; the near-term compression to 65% justifies some multiple contraction.
However, valuation becomes more attractive if revenue growth re-accelerates or gross margins rebound as the mix stabilizes. Management's target of $6.5 billion in 2030 revenue (cited in analyst commentary) implies long-run upside that is not priced into the stock if the company can prove consistent execution over the next 12-18 months.
Catalysts to watch (near- and medium-term)
- Q2 2026 results and updated guidance - a beat on revenue and signs of margin stabilization could re-rate the multiple.
- Integration progress on the Eucalyptus acquisition - successful cross-selling into Australia and adjacent markets would validate the international play.
- GLP-1 supply dynamics and partnership execution - continued fulfillment traction on branded products like Wegovy (management reported >125,000 shipments) supports the revenue pivot.
- Any signs of convertible debt conversion or buyback plans - clarity on dilution/capital allocation would reduce investor uncertainty.
- Retail/short-squeeze events - with elevated short interest, volume-driven squeezes can create outsized short-term moves.
Trade plan - actionable long
Trade direction: Long
Entry price: $31.60 - this is near the recent open and offers a better risk entry than chasing the intraday high.
Stop loss: $26.00 - just under the 50-day SMA ($26.32) and technical support zone. If price breaks below $26 with momentum, the thesis of a stabilizing recovery is in danger.
Target price: $45.00 - this represents a meaningful re-rating that would be consistent with margin re-expansion and a partial recovery toward earlier multiple compression levels.
Horizon: long term (180 trading days) - expect this position to play out over several quarters. The key catalysts (earnings, acquisition integration, GLP-1 execution) will unfold across multiple reporting periods, and the convertible debt timeline and any associated dilution clarity may take months to resolve.
Position sizing and risk: Keep position size limited given headline risk and elevated short interest. This is a trade that needs monitoring around earnings dates and any newsflow on the Eucalyptus integration or debt conversions.
Risks and counterarguments
- Margin risk: The shift to branded weight-loss products reduced gross margins from 73% to 65%. If the mix shift continues or branded supply margins stay low, adjusted EBITDA may remain depressed.
- Balance sheet/dilution risk: The $350 million zero-coupon convertible debt could lead to meaningful dilution if converted, or cash strain if repaid; debt-to-equity sits at ~2.18, implying leverage is non-trivial.
- Execution risk on international expansion: The $1.15 billion Eucalyptus acquisition increases complexity. Cross-border regulatory, pricing and integration challenges could delay synergies.
- Volatility and sentiment: HIMS has had multiple recent earnings misses; with short interest elevated, negative news can produce outsized downside.
- Regulatory/drug-access risk: Any changes in GLP-1 distribution rules, supply interruptions from manufacturers, or payer pushback could curtail sales.
Counterargument: If you believe the market is right to punish HIMS because the pivot to branded GLP-1s destroys the company’s historically attractive unit economics and growth slows materially, then long exposure is speculative. Under that view, the debt raise compounds the problem by increasing dilution risk and lowering long-term ROIC.
Why I remain bullish despite the risks
Two points keep me constructive. First, management raised guidance to $2.8-3.0 billion despite a profit miss, which indicates conviction in revenue momentum. Second, the market is already penalizing margin compression and financing risk; that means good execution or margin stabilization has asymmetric upside. The technical picture — price above the 10- and 50-day SMAs and a bullish MACD — adds tactical support for a momentum-driven recovery into the next few quarters.
What would change my mind
- Missed guidance for the next quarter or materially lower revenue than the raised full-year band (below $2.8 billion) would turn me cautious.
- Worsening margin trends with no clear path to stabilization or any large one-off cash outflows tied to the acquisition would force a reassessment.
- Any formal increase in convertible debt conversion risk or signs that the company will need additional dilutive capital within 12 months would be a major negative.
Conclusion
Hims & Hers is a high-conviction but high-volatility trade. The company has real secular opportunities in telehealth and weight-loss therapeutics and has shown the ability to grow revenue, but the transition to branded product sales, margin compression, and a large financing event have created headline-driven risk. For traders who can tolerate swings and size positions conservatively, buying near $31.60 with a strict $26 stop and a $45 target over a 180-trading-day horizon offers an asymmetric risk-reward: limited near-term capital at risk versus meaningful upside if execution and margin stabilization materialize.